23 September 2024 - Anzupgo is the first topical treatment to be specifically indicated for adult patients living with moderate to severe chronic hand eczema across the European Union for whom topical corticosteroids are inadequate or inappropriate.

Leo Pharma today announced that the European Commission has granted marketing authorisation for Anzupgo (delgocitinib) cream for the treatment of adult patients with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate.

Read Leo Pharma press release